Vanda Pharmaceuticals (VNDA) Earnings Analysis

Vanda Pharmaceuticals (VNDA) next reports earnings on 2026-07-30, consensus EPS -0.5825 USD. Last quarter (2025-10-29) it missed with EPS -0.38 USD vs -0.31 USD est (-22.6%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -1.32.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does VNDA next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate-0.5825 USD
Revenue estimate0.06B

VNDA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2025-10-29-0.38 USD-0.31 USD-22.6%Miss
2025-07-31-0.46 USD-0.34 USD-35.3%Miss
2025-02-13-0.08 USD-0.14 USD+42.9%Beat

Beat rate: 1/3 (33%) over reported quarters with consensus data.

VNDA valuation and analyst view

Trailing P/E-1.32
Trailing EPS-4.02871 USD
Price / book1.13
Dividend yield0.00%
Market cap0.33B
Analyst consensusBuy (13 buy / 5 hold / 1 sell)
Avg price target21 USD

Related research pages

Frequently asked questions

When is Vanda Pharmaceuticals (VNDA)'s next earnings date?

Vanda Pharmaceuticals is next scheduled to report on 2026-07-30, with a consensus EPS estimate of -0.5825 USD and revenue estimate of 0.06B.

Did VNDA beat earnings last quarter?

In its 2025-10-29 report, VNDA posted EPS of -0.38 USD versus a -0.31 USD estimate — a miss of 22.6%.

What is VNDA's earnings track record?

Over the last 3 reported quarters with consensus data, VNDA beat estimates 1 times (33%).

What is VNDA's current P/E ratio and EPS?

VNDA trades at a trailing P/E of -1.32 on trailing EPS of -4.028709594967586 USD.

What do analysts rate VNDA?

Analyst consensus is "Buy" across 19 ratings (0 strong buy, 13 buy, 5 hold, 1 sell, 0 strong sell). Average 12-month price target: 21 USD.